MIME-Version: 1.0 Server: WebSTAR/2.1 ID/32304 Message-ID: Date: Sat, 13 Dec 1997 21:41:51 GMT Last-Modified: Tue, 01 Jul 1997 00:17:28 GMT Content-type: text/html Content-length: 3942 MS-325


HomeAbout EPIXMS-325Technology R&DNews
PublicationsEmployment OpportunitiesInvestor InfoRequest Information


Noninvasive Cardiovascular Imaging

EPIX Medical, Inc. is developing targeted contrast agents to improve the capability of magnetic resonance imaging ("MRI") to diagnose a variety of diseases. The Company's principal product under development, MS-325, is an injectable vascular contrast agent. The Company believes that MS-325 will simplify the diagnostic pathway for a number of diseases and in many cases replace highly invasive and expensive conventional X-ray angiography. EPIX believes that MS-325 will significantly enhance the quality of images and provide physicians with a clinically superior, noninvasive and cost-effective method for diagnosing cardiovascular disease.

Conventional X-ray Angiography

Magnetic Resonance Imaging

The EPIX Solution: MRI with MS-325

MS-325 is a magnetically active, injectable small molecule. It binds to the blood protein albumin, remains at high concentrations in the bloodstream throughout the MRI exam, and is designed to be excreted safely through the kidneys over time. Because of its affinity for albumin, MS-325 provides the image time and signal strength needed to obtain a high-contrast, high-resolution image of the cardiovascular system.


FAQ's/Topics

What is Magnetic Resonance Imaging?

What is a contrast agent?

MS-325 Cardiology Indications

MS-325 Radiology Indications

The Current Procedure: X-Ray Angiography

Return to top of page.


© 1997, EPIX Medical, Inc.

E-mail us at info@epixmed.com